Page 2 - ஹட்ச்சன் சீனா மேதிட்டேச் வரையறுக்கப்பட்டவை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஹட்ச்சன் சீனா மேதிட்டேச் வரையறுக்கப்பட்டவை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஹட்ச்சன் சீனா மேதிட்டேச் வரையறுக்கப்பட்டவை Today - Breaking & Trending Today

HUTCHMED Announces US$100 Million Equity Investment by Baring Private Equity Asia


Press release content from Globe Newswire. The AP news staff was not involved in its creation.
HUTCHMED Announces US$100 Million Equity Investment by Baring Private Equity Asia
Hutchison China MediTech LimitedApril 8, 2021 GMT
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 08, 2021 (GLOBE NEWSWIRE) Hutchison China MediTech Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM) today announces that it has entered into a definitive agreement for the issuance of US$100 million of shares at a price equivalent to US$30.5 per American Depositary Share (“ADS”) via a private placement to funds affiliated with Baring Private Equity Asia (“ BPEA ”). ....

United States , Hong Kong , City Of , United Kingdom , Mark Lee , Zhou Yi , Freddy Crossley Atholl Tweedie , Ben Atwell Alex Shaw , Jean Eric Salata , Christian Hogg , Annie Cheng , Financial Conduct Authority Disclosure Guidance , London Stock Exchange , London Stock Exchange Admission , Exchange Commission , European Union Withdrawal , Hutchison China Meditech Limited , China Meditech Limited , American Depositary Share , Baring Private Equity Asia , Chief Executive Officer , Founding Partner , Share Capital , Securities Act , European Union , Shares Outstanding After ,

Investegate |Hutchison China Medi Announcements | Hutchison China Medi: $100m Investment by Baring Private Equity Asia


 
 
Hong Kong, Shanghai & Florham Park, NJ - Thursday, April 8, 2021:
Hutchison China MediTech Limited ( HUTCHMED ) (Nasdaq/AIM: HCM) today announces that it has entered into a definitive agreement for the issuance of US$100 million of shares at a price equivalent to US$30.5 per American Depositary Share ( ADS ) via a private placement to funds affiliated with Baring Private Equity Asia ( BPEA ).
 
Mr. Christian Hogg, Chief Executive Officer of HUTCHMED, said, We expect significant growth of our business this year as we look to accelerate our oncology revenues from ELUNATE
®, SULANDA
® and the potential upcoming approval of savolitinib, likely to be a first-in-class selective c-MET inhibitor in China.  We are rapidly expanding global development of our ten oncology assets, all of which were discovered in-house at HUTCHMED, and are planning to initiate 8-10 registration and registration-intent studies in 2021 ....

United States , Hong Kong , City Of , United Kingdom , Mark Lee , Zhou Yi , Freddy Crossley Atholl Tweedie , Ben Atwell Alex Shaw , Jean Eric Salata , Christian Hogg , Annie Cheng , Financial Conduct Authority Disclosure Guidance , London Stock Exchange , London Stock Exchange Admission , Exchange Commission , European Union Withdrawal , Hutchison China Meditech Limited , Equity Investment , Florham Park , American Depositary Share , Baring Private Equity Asia , Chief Executive Officer , Founding Partner , Share Capital , Securities Act , European Union ,

Hutchison China MediTech Limited (HCM) Q4 2020 Earnings Call Transcript


Executive Director and Chief Executive Officer
Okay, thank you. This is Christian Hogg, CEO of HUTCHMED. And today, we welcome everybody to this Fiscal Year 2020 Results and Business Update Presentation.
On the line I also have Dr. Wei-guo Su, our Chief Scientific Officer and Head of Research and Development; I have Johnny Cheng, our Chief Financial Officer; and I have Dr. Marek Kania, our Chief Medical Officer in the U.S. and Head of our International operations.
What I m planning to do today is, given this is an hour-long session, is spend about 30 minutes 25 minutes to 30 minutes on the presentation. I ll go through it relatively quickly as it s all fairly well laid out in our announcement that s just been out for an hour or so and then I ll leave the second half of the hour for Q&A and that s an opportunity for the broader team that we have here to answer any questions that you might have. ....

Johnny Cheng , Hutchison Medipharma , Chen Hong , Marek Kania , Savolutinib Exon , Christian Hogg , Head Of Research , Hutchison China Meditech Limited , Chief Executive , Fiscal Year , Business Update , Chief Scientific Officer , Chief Financial Officer , Chief Medical Officer , China Meditech , Hutchison China Meditech , Annual General Meeting , Chief Commercial Officer , Fast Track , ஜானி செங் , சென் ஹாங் , மரேக் கனியா , கிறிஸ்துவர் ஹாக் , தலை ஆஃப் ஆராய்ச்சி , ஹட்ச்சன் சீனா மேதிட்டேச் வரையறுக்கப்பட்டவை , தலைமை நிர்வாகி ,